0000899243-20-025332.txt : 20200916
0000899243-20-025332.hdr.sgml : 20200916
20200916163704
ACCESSION NUMBER: 0000899243-20-025332
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200914
FILED AS OF DATE: 20200916
DATE AS OF CHANGE: 20200916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Olson Lisa
CENTRAL INDEX KEY: 0001824009
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38541
FILM NUMBER: 201179195
MAIL ADDRESS:
STREET 1: C/O MAGENTA THERAPEUTICS, INC.
STREET 2: 100 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Magenta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001690585
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-201-2700
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-14
0
0001690585
Magenta Therapeutics, Inc.
MGTA
0001824009
Olson Lisa
C/O MAGENTA THERAPEUTICS, INC.
100 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Stock Option (Right to Buy)
7.77
2020-09-14
4
A
0
120000
0.00
A
2030-09-13
Common Stock
120000
120000
D
25% of this option shall vest and become exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
Head of Research and Chief Scientific Officer
/s/ Zoran Zdraveski, Attorney-in-Fact for Lisa Olson
2020-09-16